Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer

Journal of Clinical Oncology

Volumn 30, Issue 3, 2012, Pages 300-307

  Sprauten, Mette ^a   Darrah, Thomas H ^c   Peterson, Derick R ^e   Campbell, M Ellen ^c   Hannigan, Robyn E ^c   Cvancarova, Milada ^a   Beard, Clair ^d   Haugnes, Hege S ^b   Fosså, Sophie D ^a   Oldenburg, Jan ^a   Travis, Lois B ^e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PLATINUM;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE SEVERITY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NEUROTOXICITY; OTOTOXICITY; OUTCOME ASSESSMENT; PARESTHESIA; PLATINUM BLOOD LEVEL; PRIORITY JOURNAL; RATING SCALE; RAYNAUD PHENOMENON; SCALE FOR CHEMOTHERAPY INDUCED NEUROTOXICITY; TESTIS CANCER; TINNITUS;

ADOLESCENT; ADULT; CISPLATIN; COCHLEA; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PLATINUM; QUESTIONNAIRES; SURVIVAL ANALYSIS; SURVIVORS; TESTICULAR NEOPLASMS; TYMPANIC MEMBRANE; YOUNG ADULT;

EID: 84856015361     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.4025     Document Type: Article

References (64)

1. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784-796, 2007 (Pubitemid 47321601)
2. Bray F (ed): Cancer in Norway 2008. Cancer Registry of Norway, Institute of Population-Based Research, 2008
3. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41:3275-3280, 1981
4. Einhorn LH: Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99:4592-4595, 2002
5. Haugnes HS, Aass N, Fosså SD, et al: Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18:241-248, 2007 (Pubitemid 46323088)
6. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18: 1725-1732, 2000 (Pubitemid 30220551)
7. Nuver J, Smit AJ, van der Meer J, et al: Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23: 9130-9137, 2005
8. Kollmannsberger C, Hartmann JT, Kanz L, et al: Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 83:860-863, 1999
9. Travis LB, Andersson M, Gospodarowicz M, et al: Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92:1165-1171, 2000
10. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28:4649-4657, 2010
11. Travis LB, Beard C, Allan JM, et al: Testicular cancer survivorship: Research strategies and recommendations. J Natl Cancer Inst 102:1114-1130, 2010
12. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007 (Pubitemid 350013842)
13. Travis LB, Fosså SD, Schonfeld SJ, et al: Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97:1354-1365, 2005 (Pubitemid 41487803)
14. Dearnaley D, Huddart R, Horwich A: Regular review: Managing testicular cancer. BMJ 322:1583-1588, 2001 (Pubitemid 32592294)
15. Brydøy M, Oldenburg J, Klepp O, et al: Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682-1695, 2009
16. Tuxen MK, Hansen SW: Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 20:191-214, 1994 (Pubitemid 24118030)
17. Bokemeyer C, Berger CC, Kuczyk MA, et al: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14:2923-2932, 1996 (Pubitemid 26371450)
18. Windebank AJ, Grisold W: Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27-46, 2008 (Pubitemid 351393018)
19. Bokemeyer C, Berger CC, Hartmann JT, et al: Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77:1355-1362, 1998 (Pubitemid 28140629)
20. Aass N, Kaasa S, Lund E, et al: Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer 61:151-155, 1990 (Pubitemid 20043563)
21. Oldenburg J, Kraggerud SM, Brydøy M, et al: Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 5:70, 2007
22. Oldenburg J, Kraggerud SM, Cvancarova M, et al: Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25:708-714, 2007 (Pubitemid 350002927)
23. Brouwers EE, Huitema AD, Beijnen JH, et al: Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 8:7, 2008
24. Gerl A, Schierl R: Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol 39:519-522, 2000
25. Tothill P, Klys HS, Matheson LM, et al: The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 28A: 1358-1361, 1992
26. Gietema JA, Meinardi MT, Messerschmidt J, et al: Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355:1075-1076, 2000 (Pubitemid 30162815)
27. Wethal T, Haugnes HS, Kjekshus J, et al: C-reactive protein; A potential marker of second cancer and cardiovascular disease in testicular cancer survivors? Eur J Cancer 46:3425-3433, 2010
28. Peckham MJ, McElwain TJ, Barrett A, et al: Combined management of malignant teratoma of the testis. Lancet 2:267-270, 1979 (Pubitemid 9244103)
29. Kaye SB, Mead GM, Fossa S, et al: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/ European Organization for Research and Treatment of Cancer study. J Clin Oncol 16:692-701, 1998 (Pubitemid 28135617)
30. Lewis CR, Fossà SD, Mead G, et al: BOP/VIP: A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 2:203-211, 1991
31. Aass N, Klepp O, Cavallin-Stahl E, et al: Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: A multicenter experience. J Clin Oncol 9:818-826, 1991
32. Klepp O, Flodgren P, Maartman-Moe H, et al: Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer: Value of preand post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases - Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1:281-288, 1990 (Pubitemid 20377098)
33. Ozols RF, Behrens BC, Ostchega Y, et al: High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 12:59-65, 1985 (Pubitemid 16167901)
34. Lokich J, Anderson N: Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 9:13-21, 1998 (Pubitemid 28125759)
35. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422, 1999 (Pubitemid 29022420)
36. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340:351-357, 1999 (Pubitemid 29090800)
37. Horwich A, Sleijfer DT, Fosså SD, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844- 1852, 1997
38. O'Sullivan JM, Huddart RA, Norman AR, et al: Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91-96, 2003 (Pubitemid 36150265)
39. Oldenburg J, Fosså SD, Dahl AA: Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 15:791-800, 2006 (Pubitemid 43800751)
40. Fosså SD, Moynihan C, Serbouti S: Patients'and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I: A descriptive pilot study. Support Care Cancer 4:118- 128, 1996
41. Brouwers EE, Tibben MM, Pluim D, et al: Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Anal Bioanal Chem 391:577-585, 2008
42. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al: Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 1:479-488, 2009
43. Brouwers EE, Tibben MM, Rosing H, et al: Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J Mass Spectrom 41:1186-1194, 2006 (Pubitemid 44454172)
44. McLaughlin MP, Darrah TH, Holland PL: Palladium (II) and platinum(II) bind strongly to an engineered blue copper protein. Inorg Chem 50:11294- 11296, 2011
45. Brouwers EE, Tibben M, Rosing H, et al: The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. Mass Spectrom Rev 27:67-100, 2008 (Pubitemid 351315896)
46. Long GL, Winefordner JD: Limit of detection: A closer look at the IUPAC definition. Anal Chem 55:712A-724A, 1983
47. Hansen SW, Helweg-Larsen S, Trojaborg W: Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 7:1457-1461, 1989 (Pubitemid 19245115)
48. Vogelzang NJ, Bosl GJ, Johnson K, et al: Raynauds phenomenon: A common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95:288-292, 1981 (Pubitemid 11052696)
49. Krarup-Hansen A, Rietz B, Krarup C, et al: Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: An autopsy study. Neuropathol Appl Neurobiol 25:29-40, 1999 (Pubitemid 29121692)
50. Stewart DJ, Mikhael NZ, Nanji AA, et al: Renal and hepatic concentrations of platinum: Relationship to cisplatin time, dose, and nephrotoxicity. J Clin Oncol 3:1251-1256, 1985 (Pubitemid 15226531)
51. Poirier MC, Reed E, Litterst CL, et al: Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52:149-153, 1992
52. Dikhoff TG, De Goeij JJ, Mcvie JG: Long-term body retention and tissue distribution of platinum in cisplatin treated cancer patients. J Radioanal Nucl Chem 236:81-86, 1998 (Pubitemid 28481288)
53. von Schlippe M, Fowler CJ, Harland SJ: Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: Time course and prognosis. Br J Cancer 85:823-826, 2001 (Pubitemid 33010547)
54. Fosså SD, de Wit R, Roberts JT, et al: Quality of life in good prognosis patients with metastatic germ cell cancer: A prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 21:1107-1118, 2003 (Pubitemid 46594141)
55. Vaughn DJ, Palmer SC, Carver JR, et al: Cardiovascular risk in long-term survivors of testicular cancer. Cancer 112:1949-1953, 2008 (Pubitemid 351574070)
56. Woods JS: Altered porphyrin metabolism as a biomarker of mercury exposure and toxicity. Can J Physiol Pharmacol 74:210-215, 1996
57. Gagnon ZE, Newkirk C, Hicks S: Impact of platinum group metals on the environment: A toxicological, genotoxic and analytical chemistry Study. J Environ Sci Health A Tox Hazard Subst Environ Eng 41:397-414, 2006
58. Pingree SD, Simmonds PL, Rummel KT, et al: Quantitative evaluation of urinary porphyrins as a measure of kidney mercury content and mercury body burden during prolonged methylmercury exposure in rats. Toxicol Sci 61:234-240, 2001 (Pubitemid 32499391)
59. Nuver J, Smit AJ, Sleijfer DT, et al: Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 40:701-706, 2004 (Pubitemid 38326620)
60. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513-1523, 2003 (Pubitemid 46594104)
61. Wanderås EH, Fosså SD, Tretli S: Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 33:253-262, 1997
62. Chemotherapy-induced peripheral neuropathy. Meeting of the National Cancer Institute Symptom Management and Quality of Life Steering Committee, Rockville, MD, March 23, 2009
63. Albers JW, Chaudhry V, Cavaletti G, et al: Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2:CD005228, 2011
64. Bokemeyer C, Köhrmann O, Tischler J, et al: A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 7:1015-1021, 1996 (Pubitemid 27050824)